• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Franziska Michor, PhD

Publications

  • , Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH.A physical sciences network characterization of non-tumorigenic and metastatic cells.Sci Rep. 2013 Apr 25;3:1449.
    23618955
  • Ohashi K, Maruvka YE, Michor F, Pao W.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.J Clin Oncol. 2013 Mar 10;31(8):1070-80.
    23401451
  • Liu L, De S, Michor F.DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes.Nat Commun. 2013;4:1502.
    23422670
  • De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F.Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.PLoS Genet. 2013 Jan;9(1):e1003137.
    23326238
  • De S, Michor F.Analyzing the association of SCNA boundaries with replication timing.Nat Biotechnol. 2012 Nov;30(11):1045-6.
    23138296
  • Foo J, Chmielecki J, Pao W, Michor F.Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.J Thorac Oncol. 2012 Oct;7(10):1583-93.
    22982659
  • Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K.Evolutionary pathways in BRCA1-associated breast tumors.Cancer Discovery. 2012 Jun;2(6):503-11.
    22628410
  • Iwasa Y, Michor F.Evolutionary dynamics of intratumor heterogeneity.PLoS ONE. 2011;6(3):e17866.
    21479218
  • Durrett R, Foo J, Leder K, Mayberry J, Michor F.Intratumor Heterogeneity in Evolutionary Models of Tumor Progression.Genetics. 2011 Mar 15.
    21406679
  • Foo J, Leder K, Michor F.Stochastic dynamics of cancer initiation.Phys Biol. 2011 Feb;8(1):015002.
    21301064
  • De Vargas Roditi L, Michor F.Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.J Theor Biol. 2011 Mar 21;273(1):207-15.
    21194536
  • Leder K, Holland EC, Michor F.The therapeutic implications of plasticity of the cancer stem cell phenotype.PLoS ONE. 2010;5(12):e14366.
    21179426
  • Michor F, Polyak K.The Origins and Implications of Intratumor Heterogeneity.Cancer Prev Res (Phila Pa). 2010 Nov;3(11):1361-4.
    20959519
  • Attolini CS, Cheng YK, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, Mellinghoff IK, Michor F.A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17604-9.
    20864632
  • Danielson LS, Menendez S, Attolini CS, Guijarro MV, Bisogna M, Wei J, Socci ND, Levine DA, Michor F, Hernando E.A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy.Am J Pathol. 2010 Aug;177(2):908-17.
    20558575
  • Durrett R, Foo J, Leder K, Mayberry J, Michor F.Evolutionary dynamics of tumor progression with random fitness values.Theor Popul Biol. 2010 Aug;78(1):54-66.
    20488197
  • Riester M, Stephan-Otto Attolini C, Downey RJ, Singer S, Michor F.A differentiation-based phylogeny of cancer subtypes.PLoS Comput. Biol. 2010 May;6(5):e1000777.
    20463876
  • Foo J, Michor F.Evolution of resistance to anti-cancer therapy during general dosing schedules.J Theor Biol. 2010 Mar 21;263(2):179-88.
    20004211
  • Haeno H, Michor F.The evolution of tumor metastases during clonal expansion.J Theor Biol. 2010 Mar 7;263(1):30-44.
    19917298
  • Park SY, Gönen M, Kim HJ, Michor F, Polyak K.Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.J Clin Invest. 2010 Feb 1;120(2):636-44.
    20101094
  • Foo J, Michor F.Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.PLoS Comput. Biol. 2009 Nov;5(11):e1000557.
    19893626
  • Haeno H, Levine RL, Gilliland DG, Michor F.A progenitor cell origin of myeloid malignancies.Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16616-21.
    19805346
  • Michor F, Iwasa Y, Nowak MA.The age incidence of chronic myeloid leukemia can be explained by a one-mutation model.Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14931-4.
    17001000
  • Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA.Dynamics of chronic myeloid leukaemia.Nature. 2005 Jun 30;435(7046):1267-70.
    15988530